Comparative Pharmacology
Head-to-head clinical analysis: DILAUDID versus DOLENE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DILAUDID versus DOLENE.
DILAUDID vs DOLENE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dilaudid (hydromorphone) is a full opioid agonist with high affinity for mu-opioid receptors, producing analgesia by mimicking endogenous endorphins and enkephalins. It also activates kappa and delta opioid receptors to a lesser extent.
Opioid agonist, primarily mu-opioid receptor activation, leading to analgesic and euphoric effects.
Initial: 2-4 mg orally every 4-6 hours as needed; or 1-2 mg intramuscularly, subcutaneously, or intravenously every 4-6 hours as needed.
50 mg orally every 4-6 hours as needed for pain; maximum 400 mg per day.
None Documented
None Documented
2.5-3.5 hours (terminal); prolonged in hepatic/renal impairment
2.5-3.5 hours; prolonged in hepatic impairment (up to 6-8 hours) and in neonates.
Primarily renal (90% as hydromorphone-3-glucuronide and parent drug); <1% biliary/fecal
Renal: 70-80% as conjugated metabolites (mostly glucuronides), 5-10% as unchanged drug; Fecal: 5-10%; Biliary: minor.
Category C
Category C
Opioid Analgesic
Opioid Analgesic